FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update
06 août 2024 16h05 HE
|
FibroGen, Inc.
Company implementing significant cost reduction plan in the U.S. due to results in late-stage pamrevlumab pancreatic cancer trials, including a reduction of U.S. workforce by approximately 75%Focus...
FibroGen to Report Second Quarter 2024 Financial Results
30 juil. 2024 16h07 HE
|
FibroGen, Inc.
SAN FRANCISCO, July 30, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce second quarter 2024 financial results on Tuesday, August 6 after the market close. FibroGen will also...
FibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate Update
30 juil. 2024 16h05 HE
|
FibroGen, Inc.
Pamrevlumab arm of the Precision PromiseSM study in metastatic pancreatic cancer, sponsored and conducted by the Pancreatic Cancer Action Network (PanCAN), did not meet the primary endpoint of overall...
FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024
18 juin 2024 08h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, June 18, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host the second part of its virtual KOL investor event series on Wednesday, June 26, 2024 at...
FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials
03 juin 2024 16h05 HE
|
FibroGen, Inc.
FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO® in patients with select solid tumorsFibroGen to...
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
03 juin 2024 16h02 HE
|
FibroGen, Inc.
The safety and efficacy of FG-3165 will be evaluated in a Phase 1 trial in select solid tumorsPlan to begin enrollment in 2H 2024 SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen,...
FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference
03 juin 2024 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Thane Wettig, Chief Executive Officer, will participate in a Fireside Chat at Goldman Sachs 45th...
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting
23 mai 2024 17h05 HE
|
FibroGen, Inc.
FG-3246 and enzalutamide combination therapy led to a median radiographic progression free survival (rPFS) of 10.2 months in biomarker unselected patientsFG-3246 demonstrated an acceptable safety...
FibroGen to Participate in Upcoming Investor Conferences
07 mai 2024 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the company’s management will participate in the following investor conferences: Bank of America...
FibroGen Reports First Quarter 2024 Financial Results
06 mai 2024 16h02 HE
|
FibroGen, Inc.
Topline data from the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in metastatic pancreatic cancer anticipated in mid-2024Topline data from LAPIS Phase 3 study in...